<DOC>
	<DOCNO>NCT00065351</DOCNO>
	<brief_summary>For subject study consist two phase : treatment phase follow-up phase . Screening procedure take place within 28 day baseline . Treatment Phase : Subjects qualify enrollment study receive single-agent CC-5013 28-day cycle . Study visit occur every 4 week hematologic myeloma paraprotein laboratory assessment occur every 2 week first 6 cycle every 4 week thereafter . Follow-Up Phase : All subject discontinue treatment phase reason continue follow survival post-treatment phase anti-myeloma treatment .</brief_summary>
	<brief_title>Safety Efficacy Single-agent CC-5013 Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form . Age great equal 18 year time signing informed consent form . Must diagnosis multiple myeloma relapse refractory disease . Such subject relapse least partial myeloma paraprotein response ( great equal 50 % reduction myeloma paraprotein ) prior therapy continue develop disease progression despite salvage antimyeloma therapy . Subjects must document evidence disease progression therapy last prior antimyeloma treatment regimen ( must receive least 2 cycle ) prior study enrollment.Subjects may previously treat thalidomide and/or radiation therapy . Measurable level myeloma paraprotein serum ( great equal 0.5 g/dL ) urine ( great equal 0.2 g excrete 24hour collection sample ) . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 ( see Appendix II ) . Able adhere study visit schedule protocol requirement Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . Sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . WCBP must agree pregnancy test every 4 week study drug ( every 14 day woman irregular cycle ) 4 week last dose study drug . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant lactating female . Any following laboratory abnormality : A ) Absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm^3 ( 1.0 x 10^9/L ) B ) Platelet count &lt; 75,000/mm^3 ( 75 x 10^9/L ) C ) Serum creatinine &gt; 2.5 mg/dL ( 221 umol/L ) D ) Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) E ) Serum total bilirubin &gt; 2.0 mg/dL ( 34 umol/L ) Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Prior history malignancy multiple myeloma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease great equal 3 year . Prior great equal grade 3 allergic reaction/hypersensitivity thalidomide . Prior great equal grade 3 rash desquamating ( blister ) rash take thalidomide . Prior use CC5013 . Use standard/experimental antimyeloma drug therapy within 28 day initiation study drug therapy use experimental nondrug therapy within 56 day initiation study drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>MM</keyword>
	<keyword>CC5013</keyword>
	<keyword>relapsed refractory multiple myeloma</keyword>
</DOC>